Methods for the selection and cloning of nucleic acid molecules free of unwanted nucleotide sequence alterations

• US 20030143605A1
• Filed: 12/03/2002
• Published: 07/31/2003
• Est. Priority Date: 12/03/2001
• Status: Abandoned Application

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Lok, Si, Tannheimer, Stacey
• Application Number:
  US10/308,925
• Publication Number:
  US 20030143605A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6848 characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
• CPC Class Codes: C12Q 2521/325 Single stranded exonuclease
• CPC Class Codes: C12Q 2563/131 the label being a member of a cognate binding pair, i.e. extends to antibodies, haptens, avidin

Abstract

The accurate synthesis of nucleic acid molecules is important for use of amplified nucleic acid molecules as hybridization probes, in the regulation of gene expression, as templates for the production of recombinant proteins, as diagnostic probes, and in forensic analyses. Methods are provided to separate nucleic acid molecules that are free of mutations from a population of nucleic acid molecules that contain unwanted nucleotide alternations.

Claims

1. A method for eliminating an amplified nucleic acid molecule having a nucleotide sequence that is mutated, compared with the target nucleotide sequence used to produce the amplified nucleic acid molecule, comprising,

(a) obtaining a mixture of duplexes of amplified nucleic acid molecules, wherein the duplex mixture comprises homoduplexes and heteroduplexes,

(b) treating the duplex mixture with a single-strand specific nuclease that cleaves a mismatched site within a heteroduplex, and

(c) subcloning the nuclease-treated duplex mixture, wherein a cleaved duplex is unsuitable for subcloning.

2. The method of claim 1, wherein the single-strand specific nuclease is selected from the group consisting of S1 nuclease, Mung Bean endonuclease, T4 endonuclease VII, T7 endonuclease I, and CEL I.

3. The method of claim 1, wherein the nucleic acid molecule is DNA.

4. The method of claim 1, wherein the amplified nucleic acid molecules are obtained by using the polymerase chain reaction.

5. A method for eliminating an amplified nucleic acid molecule having a nucleotide sequence that is mutated, compared with the target nucleotide sequence used to produce the amplified nucleic acid molecule, comprising,

(a) obtaining a mixture of duplexes of the amplified DNA molecules, wherein the duplex mixture comprises homoduplexes and heteroduplexes,

(b) cleaving the duplex mixture with a single-strand specific nuclease that cleaves a mismatched site within a heteroduplex, wherein the cleavage produces an exposed 3′

OH moiety,

(c) treating the cleaved duplex mixture with a DNA polymerase and nucleotide analog conjugated with an affinity label to synthesize DNA that comprises the affinity label, and

(d) incubating the treated duplex mixture of (c) with an affinity label capture molecule that binds the affinity label, thereby eliminating duplexes that comprise the affinity-labeled DNA.

6. The method of claim 5, wherein the single-strand specific nuclease is selected from the group consisting of S1 nuclease, Mung Bean endonuclease, T4 endonuclease VII, T7 endonuclease I, and CEL I.

7. The method of claim 5, wherein the DNA polymerase is an enzyme with 5′

-3′

polymerase and 5′

-3′

exonuclease activities.

8. The method of claim 7, wherein the DNA polymerase is either E. coli DNA polymerase I, or Taq DNA polymerase.

9. The method of claim 5, wherein the amplified nucleic acid molecules are obtained by using the polymerase chain reaction.

10. The method of claim 5, wherein the affinity label is biotin and the affinity label capture molecule is either avidin or streptavidin.

11. The method of claim 5, wherein the affinity label capture molecule is bound to a solid support.

12. The method of claim 11, wherein the solid support is a magnetic bead.

13. A method for eliminating an amplified nucleic acid molecule having a nucleotide sequence that is mutated, compared with the target nucleotide sequence used to produce the amplified nucleic acid molecule, comprising,

(a) obtaining a mixture of duplexes of the amplified DNA molecules, wherein the duplex mixture comprises homoduplexes and heteroduplexes,

(b) treating the duplex mixture with potassium permanganate, tetraethylammonium chloride, and hydroxylamide to create carbonyl groups in mismatched nucleotides,

(c) labeling the carbonyl groups of the duplex mixture with hydrazine derivatized with an affinity label, and

(d) incubating the labeled duplex mixture of (c) with an affinity label capture molecule that binds the affinity label, thereby eliminating duplexes that comprise the affinity-labeled DNA.

14. The method of claim 13, wherein the amplified nucleic acid molecules are obtained by using the polymerase chain reaction.

15. The method of claim 13, wherein the affinity label is biotin and the affinity label capture molecule comprises either avidin or streptavidin.

16. The method of claim 13, wherein the hydrazine derivatized with biotin is selected from the group consisting of 6-((6((biotinoyl)amino)hexanoyl)amino) hexanoic acid hydrazide, N-(aminooxyacetyl)-N′

-(D-biotinyl)hydrazine, and L-lysine-N6-[5-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4oxy)-1-oxopentyl]-hydrazide.

17. The method of claim 13, wherein the affinity label capture molecule is bound to a solid support.

18. The method of claim 17, wherein the solid support is a magnetic bead.

19. A method for eliminating an amplified nucleic acid molecule having a nucleotide sequence that is mutated, compared with the target nucleotide sequence used to produce the amplified nucleic acid molecule, comprising,

(a) obtaining a mixture of duplexes of the amplified DNA molecules, wherein the duplex mixture comprises homoduplexes and heteroduplexes,

(b) treating the duplex mixture with 1-cyclohexyl-3-{2-[4-(4-methyl)morpholinyl]ethyl }carbodiimide derivatized with an affinity label, and

(c) incubating the treated duplex mixture of (c) with an affinity label capture molecule that binds the affinity label, thereby eliminating duplexes that comprise the affinity-labeled DNA.

20. The method of claim 19, wherein the amplified nucleic acid molecules are obtained by using the polymerase chain reaction.

21. The method of claim 19, wherein the affinity label is biotin and the affinity label capture molecule comprises either avidin or streptavidin.

22. The method of claim 21, wherein at least one of the carbodiimide cyclohexyl groups is replaced with biotin.

23. The method of claim 21, wherein at least one of the carbodiimide 4-methyl morpholinyl groups is replaced with biotin.

24. The method of claim 19, wherein the affinity label capture molecule is bound to a solid support.

25. The method of claim 24, wherein the solid support is a magnetic bead.